Tips and tricks in tremor treatment.
Tremor
Tremor treatment
Journal
Journal of neural transmission (Vienna, Austria : 1996)
ISSN: 1435-1463
Titre abrégé: J Neural Transm (Vienna)
Pays: Austria
ID NLM: 9702341
Informations de publication
Date de publication:
24 Jul 2024
24 Jul 2024
Historique:
received:
09
04
2024
accepted:
04
07
2024
medline:
24
7
2024
pubmed:
24
7
2024
entrez:
23
7
2024
Statut:
aheadofprint
Résumé
Tremor, whether arising from neurological diseases, other conditions, or medication side effects, significantly impacts patients' lives. Treatment complexities necessitate clear algorithms and strategies. Levodopa remains pivotal for Parkinson's tremor, though response variability exists. Some dopamine agonists offer notable tremor reduction targeting D2 receptors. Propranolol effectively manages essential tremor and essential tremor plus (ET/ET +), sometimes with primidone for added benefits, albeit dose-dependent side effects. As reserve medications anticholinergics and clozapine are used for treatment of parkinsonian tremor, 1-Octanol and certain anticonvulsant drugs for tremor of other orign, especially ET. Therapies such as invasive deep brain stimulation and lesional focused ultrasound serve for resistant cases. A medication review is crucial for all forms of tremor, but it is particularly important if medication may have triggered the tremor. Sensor-based detection and non-drug interventions like wristbands and physical therapy broaden diagnostic and therapeutic horizons, promising future tremor care enhancements. Understanding treatment nuances is a key for tailored tremor management respecting patient needs and tolerability. Successful strategies integrate pharmacological, non-invasive, and technological modalities, aiming for optimal symptom control and improved quality of life.
Identifiants
pubmed: 39043978
doi: 10.1007/s00702-024-02806-x
pii: 10.1007/s00702-024-02806-x
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Abila B, Lazarus JH, Kingswood JC, Marshall RW, Wilson JF, Richens A (1985) Tremor: an alternative approach for investigating adrenergic mechanisms in thyrotoxicosis? Clin Sci (lond) 69(4):459–463
pubmed: 2864158
doi: 10.1042/cs0690459
Aldred J, Freire-Alvarez E, Amelin AV et al (2023) Continuous subcutaneous foslevodopa/foscarbidopa in parkinson’s disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study. Neurol Ther 12(6):1937–1958
pubmed: 37632656
pmcid: 10630297
doi: 10.1007/s40120-023-00533-1
Alexander SP, Christopoulos A, Davenport AP et al (2021) The concise guide to pharmacology 2021/22: G protein-coupled receptors. Br J Pharmacol 178(Suppl 1):S27–S156
pubmed: 34529832
Alonso-Juarez M, Torres-Russotto D, Crespo-Morfin P, Baizabal-Carvallo JF (2017) The clinical features and functional impact of valproate-induced tremor. Parkinsonism Relat Disord 44:147–150
pubmed: 28941829
doi: 10.1016/j.parkreldis.2017.09.011
Anandan C, Jankovic J (2021) Botulinum toxin in movement disorders: an update. Toxins (basel) 13(1):42
pubmed: 33430071
pmcid: 7827923
doi: 10.3390/toxins13010042
Anandan C, Jankovic J (2024) Botulinum toxin treatment in parkinsonism. J Neurol Sci 456:122810
pubmed: 38056063
doi: 10.1016/j.jns.2023.122810
Baek JH, Kinrys G, Nierenberg AA (2014) Lithium tremor revisited: pathophysiology and treatment. Acta Psychiatr Scand 129(1):17–23
pubmed: 23834617
doi: 10.1111/acps.12171
Baldwin DS, Montgomery SA, Nil R, Lader M (2007) Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 10(1):73–84
pubmed: 16359583
doi: 10.1017/S1461145705006358
Bartl M, Dakna M, Schade S et al (2022) Longitudinal change and progression indicators using the movement disorder society-unified Parkinson’s disease rating scale in two independent cohorts with early parkinson’s disease. J Parkinsons Dis 12(1):437–452
pubmed: 34719511
doi: 10.3233/JPD-212860
Beaulieu M (1987) Clinical importance of D-1 and D-2 receptors. Can J Neurol Sci 14(3 Suppl):402–406
pubmed: 2960428
doi: 10.1017/S031716710003780X
Benabid AL, Pollak P, Gervason C et al (1991) Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 337(8738):403–406
pubmed: 1671433
doi: 10.1016/0140-6736(91)91175-T
Bhatia KP, Bain P, Bajaj N et al (2018) Consensus Statement on the classification of tremors from the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord 33(1):75–87
pubmed: 29193359
doi: 10.1002/mds.27121
Biary N, Koller W (1987) Kinetic predominant essential tremor: successful treatment with clonazepam. Neurology 37(3):471–474
pubmed: 3822141
doi: 10.1212/WNL.37.3.471
Biary N, Bahou Y, Sofi MA, Thomas W, Al Deeb SM (1995) The effect of nimodipine on essential tremor. Neurology 45(8):1523–1525
pubmed: 7644052
doi: 10.1212/WNL.45.8.1523
Blomstedt P, Hariz GM, Hariz MI, Koskinen LO (2007) Thalamic deep brain stimulation in the treatment of essential tremor: a long-term follow-up. Br J Neurosurg 21(5):504–509
pubmed: 17922323
doi: 10.1080/02688690701552278
Blomstedt P, Sandvik U, Tisch S (2010) Deep brain stimulation in the posterior subthalamic area in the treatment of essential tremor. Mov Disord 25(10):1350–1356
pubmed: 20544817
doi: 10.1002/mds.22758
Bonuccelli U, Ceravolo R, Salvetti S et al (1997) Clozapine in Parkinson’s disease tremor. effects of acute and chronic administration. Neurology 49(6):1587–1590
pubmed: 9409351
doi: 10.1212/WNL.49.6.1587
Bunzow JR, Van Tol HH, Grandy DK et al (1988) Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 336(6201):783–787
pubmed: 2974511
doi: 10.1038/336783a0
Burgess S, Geddes J, Hawton K, Townsend E, Jamison K, Goodwin G (2001) Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003013
doi: 10.1002/14651858.CD003013
pubmed: 11687035
pmcid: 7005360
Bushara KO, Goldstein SR, Grimes GJ Jr, Burstein AH, Hallett M (2004) Pilot trial of 1-octanol in essential tremor. Neurology 62(1):122–124
pubmed: 14718713
doi: 10.1212/01.WNL.0000101722.95137.19
Cagnan H, Pedrosa D, Little S et al (2016) Stimulating at the right time: phase-specific deep brain stimulation. Brain 140(1):132–145
pubmed: 28007997
pmcid: 5226063
doi: 10.1093/brain/aww286
Chagas MHN, Zuardi AW, Tumas V et al (2014) Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial. J Psychopharmacol 28(11):1088–1098
pubmed: 25237116
doi: 10.1177/0269881114550355
Chang KH, Wang SH, Chi CC (2015) Efficacy and safety of topiramate for essential tremor: a meta-analysis of randomized controlled trials. Medicine (baltimore) 94(43):e1809
pubmed: 26512577
doi: 10.1097/MD.0000000000001809
Chang JW, Park CK, Lipsman N et al (2018) A prospective trial of magnetic resonance-guided focused ultrasound thalamotomy for essential tremor: results at the 2-year follow-up. Ann Neurol 83(1):107–114
pubmed: 29265546
doi: 10.1002/ana.25126
Charness ME, Morady F, Scheinman MM (1984) Frequent neurologic toxicity associated with amiodarone therapy. Neurology 34(5):669–669
pubmed: 6538658
doi: 10.1212/WNL.34.5.669
Chayasirisobhon S (2020) Mechanisms of action and pharmacokinetics of cannabis. Perm J 25:1–3
pubmed: 33635777
Chen W, Hopfner F, Becktepe JS, Deuschl G (2017) Rest tremor revisited: Parkinson’s disease and other disorders. Transl Neurodegener 6:16
pubmed: 28638597
pmcid: 5472969
doi: 10.1186/s40035-017-0086-4
Chien EY, Liu W, Zhao Q et al (2010) Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330(6007):1091–1095
pubmed: 21097933
pmcid: 3058422
doi: 10.1126/science.1197410
Cilia R, Akpalu A, Sarfo FS et al (2014) The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain 137(Pt 10):2731–2742
pubmed: 25034897
pmcid: 4163032
doi: 10.1093/brain/awu195
Connor GS, Edwards K, Tarsy D (2008) Topiramate in essential tremor: findings from double-blind, placebo-controlled, crossover trials. Clin Neuropharmacol 31(2):97–103
pubmed: 18382182
doi: 10.1097/WNF.0b013e3180d09969
Crystal HA (1986) Duration of effectiveness of primidone in essential tremor. Neurology 36(11):1543
pubmed: 3762978
doi: 10.1212/WNL.36.11.1543
Cury RG, Fraix V, Castrioto A et al (2017) Thalamic deep brain stimulation for tremor in Parkinson disease, essential tremor, and dystonia. Neurology 89(13):1416–1423
pubmed: 28768840
doi: 10.1212/WNL.0000000000004295
Dai D, Fernandes J, Kim H, Coetzer H (2023) Comparative effectiveness of transcutaneous afferent patterned stimulation therapy for essential tremor: a randomized pragmatic clinical trial. Tremor Other Hyperkinet Mov (n Y) 13:38
pubmed: 37869579
doi: 10.5334/tohm.798
Davis TL, Charles PD, Burns RS (1995) Clonazepam-sensitive intermittent dystonic tremor. South Med J 88(10):1069–1071
pubmed: 7481966
doi: 10.1097/00007611-199510000-00014
de Lau LM, Breteler MM (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5(6):525–535
pubmed: 16713924
doi: 10.1016/S1474-4422(06)70471-9
de Faria SM, de Morais FD, Tumas V et al (2020) Effects of acute cannabidiol administration on anxiety and tremors induced by a simulated public speaking test in patients with Parkinson’s disease. J Psychopharmacol 34(2):189–196
pubmed: 31909680
doi: 10.1177/0269881119895536
Dennison U, Clarkson M, O’Mullane J, Cassidy EM (2011) The incidence and clinical correlates of lithium toxicity: a retrospective review. I J Med Sci 180(3):661–665. https://doi.org/10.1007/s11845-011-0712-6
doi: 10.1007/s11845-011-0712-6
Deuschl G, Krack P, Lauk M, Timmer J (1996) Clinical neurophysiology of tremor. J Clin Neurophysiol 13(2):110–121
pubmed: 8849966
doi: 10.1097/00004691-199603000-00002
Deuschl G, Raethjen J, Hellriegel H, Elble R (2011) Treatment of patients with essential tremor. Lancet Neurol 10(2):148–161
pubmed: 21256454
doi: 10.1016/S1474-4422(10)70322-7
Deuschl G, Becktepe JS, Dirkx M et al (2022) The clinical and electrophysiological investigation of tremor. Clin Neurophysiol 136:93–129
pubmed: 35149267
doi: 10.1016/j.clinph.2022.01.004
Deuschl G, Pea S, Tremor (2022) S2k-Leitlinie in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. Online: www.dgn.org/leitlinien
di Biase L, Brittain JS, Shah SA et al (2017) Tremor stability index: a new tool for differential diagnosis in tremor syndromes. Brain 140(7):1977–1986
pubmed: 28459950
doi: 10.1093/brain/awx104
Diaz-Martinez A, Benassinni O, Ontiveros A et al (1998) A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. Clin Ther 20(3):467–476
pubmed: 9663362
doi: 10.1016/S0149-2918(98)80056-8
D’Souza M, Chen KS, Rosenberg J et al (2019) Impact of skull density ratio on efficacy and safety of magnetic resonance-guided focused ultrasound treatment of essential tremor. J Neurosurg 132(5):1392–1397
pubmed: 31026836
doi: 10.3171/2019.2.JNS183517
Elias WJ, Huss D, Voss T et al (2013) A pilot study of focused ultrasound thalamotomy for essential tremor. N Engl J Med 369(7):640–648
pubmed: 23944301
doi: 10.1056/NEJMoa1300962
Engel K, Huckhagel T, Gulberti A et al (2018) Towards unambiguous reporting of complications related to deep brain stimulation surgery: a retrospective single-center analysis and systematic review of the literature. PLoS ONE 13(8):e0198529
pubmed: 30071021
pmcid: 6071984
doi: 10.1371/journal.pone.0198529
Espay AJ, Lang AE, Erro R et al (2017) Essential pitfalls in “essential” tremor. Mov Disord 32(3):325–331
pubmed: 28116753
pmcid: 5359065
doi: 10.1002/mds.26919
Fahn S, Elton RL (2003) Movement disorder society task force on rating scales for Parkinson’s D The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 18(7):738–750
doi: 10.1002/mds.10473
Fahn S, Oakes D, Shoulson I et al (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351(24):2498–2508
pubmed: 15590952
doi: 10.1056/NEJMoa033447
Fasano A, Bove F, Lang AE (2014) The treatment of dystonic tremor: a systematic review. J Neurol Neurosurg Psychiatry 85(7):759–769
pubmed: 24167042
doi: 10.1136/jnnp-2013-305532
Ferreira JJ, Mestre TA, Lyons KE et al (2019) MDS evidence-based review of treatments for essential tremor. Mov Disord 34(7):950–958
pubmed: 31046186
doi: 10.1002/mds.27700
Findley LJ, Cleeves L, Calzetti S (1985) Primidone in essential tremor of the hands and head: a double blind controlled clinical study. J Neurol Neurosurg Psychiatry 48(9):911–915
pubmed: 3900296
pmcid: 1028493
doi: 10.1136/jnnp.48.9.911
Fox SH, Katzenschlager R, Lim SY et al (2018) International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord 33(8):1248–1266
pubmed: 29570866
doi: 10.1002/mds.27372
Friedman JH, Koller WC, Lannon MC, Busenbark K, Swanson-Hyland E, Smith D (1997) Benztropine versus clozapine for the treatment of tremor in Parkinson’s disease. Neurology 48(4):1077–1081
pubmed: 9109903
doi: 10.1212/WNL.48.4.1077
Fuchs C, Nobile MS, Zamora G, Degeneffe A, Kubben P, Kaymak U (2021) Tremor assessment using smartphone sensor data and fuzzy reasoning. BMC Bioinform 22(Suppl 2):57
doi: 10.1186/s12859-021-03961-8
Fytagoridis A, Astrom M, Samuelsson J, Blomstedt P (2016) Deep brain stimulation of the caudal zona incerta: tremor control in relation to the location of stimulation fields. Stereotact Funct Neurosurg 94(6):363–370
pubmed: 27784023
doi: 10.1159/000448926
Gallay MN, Moser D, Rossi F et al (2016) Incisionless transcranial MR-guided focused ultrasound in essential tremor: cerebellothalamic tractotomy. J Ther Ultrasound 4:5
pubmed: 26877873
pmcid: 4752806
doi: 10.1186/s40349-016-0049-8
Galvez-Jimenez N, Hargreave M (2000) Topiramate and essential tremor. Ann Neurol 47(6):837–838
pubmed: 10852557
doi: 10.1002/1531-8249(200006)47:6<837::AID-ANA24>3.0.CO;2-2
Gardner J (2013) A history of deep brain stimulation: Technological innovation and the role of clinical assessment tools. Soc Stud Sci 43(5):707–728
pmcid: 3785222
doi: 10.1177/0306312713483678
Gershanik O, Heikkila RE, Duvoisin RC (1983) Behavioral correlations of dopamine receptor activation. Neurology 33(11):1489–1492
pubmed: 6605497
doi: 10.1212/WNL.33.11.1489
Gijtenbeek JMM, van den Bent MJ, Vecht CJ (1999) Cyclosporine neurotoxicity: a review. J Neurol 246(5):339–346
pubmed: 10399863
doi: 10.1007/s004150050360
Gupta DK, Marano M, Zweber C, Boyd JT, Kuo SH (2020) Prevalence and relationship of rest tremor and action tremor in Parkinson’s disease. Tremor Other Hyperkinet Mov (n Y) 10:58
pubmed: 33384882
doi: 10.5334/tohm.552
Hamed SA, Abdellah MM (2017) The relationship between valproate induced tremors and circulating neurotransmitters: a preliminary study. Int J Neurosci 127(3):236–242
pubmed: 27161592
doi: 10.1080/00207454.2016.1181631
Harary M, Segar DJ, Hayes MT, Cosgrove GR (2019) Unilateral thalamic deep brain stimulation versus focused ultrasound thalamotomy for essential tremor. World Neurosurg 126:e144–e152
pubmed: 30794976
doi: 10.1016/j.wneu.2019.01.281
Hariz GM, Lindberg M, Bergenheim AT (2002) Impact of thalamic deep brain stimulation on disability and health-related quality of life in patients with essential tremor. J Neurol Neurosurg Psychiatry 72(1):47–52
pubmed: 11784825
pmcid: 1737710
doi: 10.1136/jnnp.72.1.47
Haubenberger D, Nahab FB, Voller B, Hallett M (2014) Treatment of essential tremor with long-chain alcohols: still experimental or ready for prime time? Tremor Other Hyperkinet Mov (n y). https://doi.org/10.5334/tohm.232
doi: 10.5334/tohm.232
pubmed: 24587968
Hedera P (2017) Emerging strategies in the management of essential tremor. Ther Adv Neurol Disord 10(2):137–148
pubmed: 28382111
doi: 10.1177/1756285616679123
Henderson JM, Yiannikas C, Morris JG, Einstein R, Jackson D, Byth K (1994) Postural tremor of Parkinson’s disease. Clin Neuropharmacol 17(3):277–285
pubmed: 9316673
doi: 10.1097/00002826-199406000-00007
Hilger D, Masureel M, Kobilka BK (2018) Structure and dynamics of GPCR signaling complexes. Nat Struct Mol Biol 25(1):4–12
pubmed: 29323277
pmcid: 6535338
doi: 10.1038/s41594-017-0011-7
Höglinger G, T Cea (2023) Parkinson-Krankheit, S2k-Leitlinie, , in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. Online: www.dgn.org/leitlinien (abgerufen am 02.02.2024)
Hopfner F, Deuschl G (2018) Is essential tremor a single entity? Eur J Neurol 25(1):71–82
pubmed: 28905504
doi: 10.1111/ene.13454
Hopfner F, Deuschl G (2020) Managing Essential Tremor. Neurotherapeutics 17(4):1603–1621
pubmed: 32915385
pmcid: 7851235
doi: 10.1007/s13311-020-00899-2
Hopfner F, Erhart T, Knudsen K et al (2015) Testing for alcohol sensitivity of tremor amplitude in a large cohort with essential tremor. Parkinsonism Relat Disord 21(8):848–851
pubmed: 26002382
doi: 10.1016/j.parkreldis.2015.05.005
Hopfner F, Hoglinger GU, Kuhlenbaumer G et al (2020) beta-adrenoreceptors and the risk of Parkinson’s disease. Lancet Neurol 19(3):247–254
pubmed: 31999942
doi: 10.1016/S1474-4422(19)30400-4
Hubble JP, Busenbark KL, Wilkinson S et al (1997) Effects of thalamic deep brain stimulation based on tremor type and diagnosis. Mov Disord 12(3):337–341
pubmed: 9159728
doi: 10.1002/mds.870120312
Hughes AJ, Lees AJ, Stern GM (1990) Apomorphine in the diagnosis and treatment of parkinsonian tremor. Clin Neuropharmacol 13(4):312–317
pubmed: 2208183
doi: 10.1097/00002826-199008000-00005
Huss DS, Dallapiazza RF, Shah BB, Harrison MB, Diamond J, Elias WJ (2015) Functional assessment and quality of life in essential tremor with bilateral or unilateral DBS and focused ultrasound thalamotomy. Mov Disord 30(14):1937–1943
pubmed: 26769606
doi: 10.1002/mds.26455
Isaacson SH, Peckham E, Tse W et al (2020) Prospective home-use study on non-invasive neuromodulation therapy for essential tremor. Tremor Other Hyperkinet Mov (n Y) 10:29
pubmed: 32864188
doi: 10.5334/tohm.59
Ishida S, Sugino M, Hosokawa T et al (2010) Amiodarone-induced liver cirrhosis and parkinsonism: a case report. Clin Neuropathol 29(2):84–88
pubmed: 20175957
doi: 10.5414/NPP29084
Jankovic J, Fahn S (1986) A survey of 100 patients with tremor. Mov Disord 1(2):61–69. https://doi.org/10.1002/mds.870010204
doi: 10.1002/mds.870010204
Jankovic J, Schwartz K (1991) Botulinum toxin treatment of tremors. Neurology 41(8):1185–1188
pubmed: 1866001
doi: 10.1212/WNL.41.8.1185
Junker J, Brandt V, Berman BD et al (2018) Predictors of alcohol responsiveness in dystonia. Neurology 91(21):e2020–e2026
pubmed: 30341158
pmcid: 6260199
doi: 10.1212/WNL.0000000000006551
Kanner AM, Parra J, Frey M (2000) The, “forgotten” cross-tolerance between phenobarbital and primidone: it can prevent acute primidone-related toxicity. Epilepsia 41(10):1310–1314
pubmed: 11051127
doi: 10.1111/j.1528-1157.2000.tb04610.x
Kishimoto M, Adachi M, Takahashi K, Washizaki K (2019) Clonazepam-induced liver dysfunction, severe hyperlipidaemia, and hyperglycaemic crisis: a case report. SAGE Open Med Case Rep 7:2050313X19842976
pubmed: 31001426
pmcid: 6454642
Kleinholdermann U, Wullstein M, Pedrosa D (2021) Prediction of motor Unified Parkinson’s disease rating scale scores in patients with Parkinson’s disease using surface electromyography. Clin Neurophysiol 132(7):1708–1713
pubmed: 33958263
doi: 10.1016/j.clinph.2021.01.031
Kleinholdermann U, Bacara B, Timmermann L, Pedrosa DJ (2023) Prediction of movement ratings and deep brain stimulation parameters in idiopathic Parkinson’s Disease. Neuromodulation 26(2):356–363
pubmed: 36396526
doi: 10.1016/j.neurom.2022.09.010
Knudsen K, Lorenz D, Deuschl G (2011) A clinical test for the alcohol sensitivity of essential tremor. Mov Disord 26(12):2291–2295
pubmed: 22021159
doi: 10.1002/mds.23846
Koller WC (1986) Pharmacologic treatment of parkinsonian tremor. Arch Neurol 43(2):126–127
pubmed: 3947248
doi: 10.1001/archneur.1986.00520020020009
Koller WC, Royse VL (1986) Efficacy of primidone in essential tremor. Neurology 36(1):121–124
pubmed: 3941767
doi: 10.1212/WNL.36.1.121
Koller WC, Vetere-Overfield B (1989) Acute and chronic effects of propranolol and primidone in essential tremor. Neurology 39(12):1587–1588
pubmed: 2586774
doi: 10.1212/WNL.39.12.1587
Krack P, Benazzouz A, Pollak P et al (1998) Treatment of tremor in Parkinson’s disease by subthalamic nucleus stimulation. Mov Disord 13(6):907–914
pubmed: 9827614
doi: 10.1002/mds.870130608
Kubota KJ, Chen JA, Little MA (2016) Machine learning for large-scale wearable sensor data in Parkinson’s disease: concepts, promises, pitfalls, and futures. Mov Disord 31(9):1314–1326
pubmed: 27501026
doi: 10.1002/mds.26693
Kurata Y, Marszalec W, Yeh JZ, Narahashi T (1999) Agonist and potentiation actions of n-octanol on gamma-aminobutyric acid type A receptors. Mol Pharmacol 55(6):1011–1019
pubmed: 10347242
doi: 10.1124/mol.55.6.1011
Lenka A, Louis ED (2021) Primidone intolerance in essential tremor: is it more than just age? Tremor Other Hyperkinet Mov (n Y) 11:57
pubmed: 35070493
doi: 10.5334/tohm.672
Lenkapothula N, Cascella M. Primidone. StatPearls (2024) Treasure Island (FL) ineligible companies. Disclosure: Marco Cascella declares no relevant financial relationships with ineligible companies
Lester-Smith RA, Miller CH, Cherney LR (2023) Behavioral therapy for tremor or dystonia affecting voice in speakers with hyperkinetic dysarthria: a systematic review. J Voice 37(4):561–573
pubmed: 34112549
doi: 10.1016/j.jvoice.2021.03.026
Lim WS, Chiu S-I, Wu M-C et al (2022) An integrated biometric voice and facial features for early detection of Parkinson’s disease. Npj Parkinson’s Disease 8(1):145
pubmed: 36309501
pmcid: 9617232
doi: 10.1038/s41531-022-00414-8
Lorenz D, Schwieger D, Moises H, Deuschl G (2006) Quality of life and personality in essential tremor patients. Mov Disord 21(8):1114–1118
pubmed: 16622851
doi: 10.1002/mds.20884
Louis ED (2023) Essential tremor. Handb Clin Neurol 196:389–401
pubmed: 37620080
doi: 10.1016/B978-0-323-98817-9.00012-0
Louis ED, Ferreira JJ (2010) How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord 25(5):534–541
pubmed: 20175185
doi: 10.1002/mds.22838
Louis ED, Ford B, Barnes LF (2000) Clinical subtypes of essential tremor. Arch Neurol 57(8):1194–1198
pubmed: 10927801
doi: 10.1001/archneur.57.8.1194
Luo L, Andrews H, Alcalay RN et al (2019) Motor phenotype classification in moderate to advanced PD in BioFIND study. Parkinsonism Relat Disord 65:178–183
pubmed: 31255537
pmcid: 6774826
doi: 10.1016/j.parkreldis.2019.06.017
Luo S, Zou H, Stebbins GT et al (2022) Dissecting the domains of Parkinson’s disease: insights from longitudinal item response theory modeling. Mov Disord 37(9):1904–1914
pubmed: 35841312
pmcid: 9897939
doi: 10.1002/mds.29154
Ma LH, Jia L, Bai L (2023) Safety outcomes of salbutamol: A systematic review and meta-analysis. Clin Respir J 17(12):1254–1264
pubmed: 37844914
pmcid: 10730473
doi: 10.1111/crj.13711
Masellis M, Collinson S, Freeman N et al (2016) Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson’s disease: a pharmacogenetic study. Brain 139(Pt 7):2050–2062
pubmed: 27190009
doi: 10.1093/brain/aww109
McGurrin P, Norato G, Thompson-Westra J et al (2024) Objective response to ethanol in essential tremor: results from a standardized ethanol challenge study. Ann Clin Transl Neurol 11(1):156–168
pubmed: 38087917
doi: 10.1002/acn3.51943
Mehta SH, Morgan JC, Sethi KD (2015) Drug-induced movement disorders. Neurol Clin 33(1):153–174
pubmed: 25432728
doi: 10.1016/j.ncl.2014.09.011
Meng Y, Solomon B, Boutet A et al (2018) Magnetic resonance-guided focused ultrasound thalamotomy for treatment of essential tremor: a 2-year outcome study. Mov Disord 33(10):1647–1650
pubmed: 30288794
doi: 10.1002/mds.99
Millan MJ (2010) From the cell to the clinic: a comparative review of the partial D(2)/D(3)receptor agonist and alpha2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson’s disease. Pharmacol Ther 128(2):229–273
pubmed: 20600305
doi: 10.1016/j.pharmthera.2010.06.002
Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. a multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303(2):791–804
pubmed: 12388666
doi: 10.1124/jpet.102.039867
Mittal SO, Lenka A, Jankovic J (2019) Botulinum toxin for the treatment of tremor. Parkinsonism Relat Disord 63:31–41
pubmed: 30709779
doi: 10.1016/j.parkreldis.2019.01.023
Mo J, Priefer R (2021) Medical devices for tremor suppression: current status and future directions. Biosensors (basel) 11(4):99
pubmed: 33808056
doi: 10.3390/bios11040099
Mohammed N, Patra D, Nanda A (2018) A meta-analysis of outcomes and complications of magnetic resonance-guided focused ultrasound in the treatment of essential tremor. Neurosurg Focus 44(2):E4
pubmed: 29385917
doi: 10.3171/2017.11.FOCUS17628
Morgan JC, Sethi KD (2005) Drug-induced tremors. Lancet Neurol 4(12):866–876
pubmed: 16297844
doi: 10.1016/S1474-4422(05)70250-7
Mostile G, Jankovic J (2010) Alcohol in essential tremor and other movement disorders. Mov Disord 25(14):2274–2284
pubmed: 20721919
doi: 10.1002/mds.23240
Nahab FB, Wittevrongel L, Ippolito D et al (2011) An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor. Neurotherapeutics 8(4):753–762
pubmed: 21594724
pmcid: 3250299
doi: 10.1007/s13311-011-0045-1
Newman-Tancredi A, Cussac D, Quentric Y et al (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. agonist and antagonist properties at Serotonin, 5-HT<sub>1</sub> and 5-HT<sub>2</sub>, receptor subtypes. J Pharmacol Exp Ther 303(2):815–822
pubmed: 12388668
doi: 10.1124/jpet.102.039883
Newman-Tancredi A, Cussac D, Audinot V et al (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic RECEPTOR II agonist and antagonist properties at subtypes of dopamine D2-like receptor and α<sub>1</sub>/α<sub>2</sub>-Adrenoceptor. J Pharmacol Exp Ther 303(2):805–814
pubmed: 12388667
doi: 10.1124/jpet.102.039875
Okun MS (2012) Deep-brain stimulation for Parkinson’s disease. N Engl J Med 367(16):1529–1538
pubmed: 23075179
doi: 10.1056/NEJMct1208070
Olanow CW, Kieburtz K, Odin P et al (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13(2):141–149
pubmed: 24361112
doi: 10.1016/S1474-4422(13)70293-X
Olanow CW, Poewe W, Rascol O, Stocchi F (2021) On-Demand therapy for OFF episodes in Parkinson’s disease. Mov Disord 36(10):2244–2253
pubmed: 34363424
doi: 10.1002/mds.28726
Ondo W (2022) Chapter eleven - enhancing GABA inhibition is the next generation of medications for essential tremor. In: Kuo S-H, Louis ED (eds) International Review of Neurobiology. Academic Press, pp 317–334
Ondo W, Hashem V, LeWitt PA et al (2018) Comparison of the fahn-tolosa-marin clinical rating scale and the essential tremor rating assessment scale. Mov Disord Clin Pract 5(1):60–65
pubmed: 30363460
doi: 10.1002/mdc3.12560
Orr CF, Ahlskog JE (2009) Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol 66(7):865–869
pubmed: 19597088
doi: 10.1001/archneurol.2009.96
O’Suilleabhain P, Dewey RB Jr (2002) Randomized trial comparing primidone initiation schedules for treating essential tremor. Mov Disord 17(2):382–386
pubmed: 11921128
doi: 10.1002/mds.10083
O’Sullivan SS, Evans AH, Lees AJ (2009) Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 23(2):157–170
pubmed: 19173374
doi: 10.2165/00023210-200923020-00005
Pappert EJ, Germanson T, Myobloc/Neurobloc European Cervical Dystonia Study G (2008) Botulinum toxin type B vs type A in toxin-naive patients with cervical dystonia: Randomized, double-blind, noninferiority trial. Mov Disord 23(4):510–517
pubmed: 18098274
doi: 10.1002/mds.21724
Park YS, Jung NY, Na YC, Chang JW (2019) Four-year follow-up results of magnetic resonance-guided focused ultrasound thalamotomy for essential tremor. Mov Disord 34(5):727–734
pubmed: 30759322
doi: 10.1002/mds.27637
Paschen S, Forstenpointner J, Becktepe J et al (2019) Long-term efficacy of deep brain stimulation for essential tremor: An observer-blinded study. Neurology 92(12):e1378–e1386
pubmed: 30787161
doi: 10.1212/WNL.0000000000007134
Pfeiffer C, Wagner ML (1994) Clozapine therapy for Parkinson’s disease and other movement disorders. Am J Hosp Pharm 51(24):3047–3053
pubmed: 7856623
Pirker W, Katzenschlager R, Hallett M, Poewe W (2023) Pharmacological treatment of tremor in Parkinson’s disease revisited. J Parkinsons Dis 13(2):127–144
pubmed: 36847017
pmcid: 10041452
doi: 10.3233/JPD-225060
Raethjen J, Lemke MR, Lindemann M, Wenzelburger R, Krack P, Deuschl G (2001) Amitriptyline enhances the central component of physiological tremor. J Neurol Neurosurg Psychiatry 70(1):78–82
pubmed: 11118252
pmcid: 1763454
doi: 10.1136/jnnp.70.1.78
Rajput AH, Rajput A (2014) Medical treatment of essential tremor. J Cent Nerv Syst Dis 6:29–39
pubmed: 24812533
pmcid: 3999812
doi: 10.4137/JCNSD.S13570
Ravikumar VK, Parker JJ, Hornbeck TS et al (2017) Cost-effectiveness of focused ultrasound, radiosurgery, and DBS for essential tremor. Mov Disord 32(8):1165–1173
pubmed: 28370272
doi: 10.1002/mds.26997
Santos de Alencar S, Crippa JAS, Brito MCM, Pimentel AV, Cecilio Hallak JE, Tumas V (2021) A single oral dose of cannabidiol did not reduce upper limb tremor in patients with essential tremor. Parkinsonism Relat Disord 83:37–40
pubmed: 33465546
doi: 10.1016/j.parkreldis.2021.01.001
Sasikumar S, Matta R, Munhoz RP et al (2021) Advanced therapies for the management of dopamine dysregulation syndrome in Parkinson’s disease. Mov Disord Clin Pract 8(3):400–405
pubmed: 33816669
pmcid: 8015898
doi: 10.1002/mdc3.13154
Sasso E, Perucca E, Fava R, Calzetti S (1990) Primidone in the long-term treatment of essential tremor: a prospective study with computerized quantitative analysis. Clin Neuropharmacol 13(1):67–76
pubmed: 2306749
doi: 10.1097/00002826-199002000-00007
Schreglmann SR, Bauer R, Hagele-Link S et al (2017) Unilateral cerebellothalamic tract ablation in essential tremor by MRI-guided focused ultrasound. Neurology 88(14):1329–1333
pubmed: 28275083
doi: 10.1212/WNL.0000000000003795
Schwingenschuh P, Espay AJ (2022) Functional tremor. J Neurol Sci 435:120208
pubmed: 35306423
doi: 10.1016/j.jns.2022.120208
Seeman P (2015) Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 69(4):183–189
pubmed: 25645960
doi: 10.1002/syn.21805
Seppi K, Ray Chaudhuri K, Coelho M et al (2019) Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord 34(2):180–198
pubmed: 30653247
pmcid: 6916382
doi: 10.1002/mds.27602
Serrano-Duenas M (2002) Fluoxetine-induced tremor: clinical features in 21 patients. Parkinsonism Relat Disord 8(5):325–327
pubmed: 15177061
doi: 10.1016/S1353-8020(01)00043-8
Serrano-Duenas M (2003) Use of primidone in low doses (250 mg/day) versus high doses (750 mg/day) in the management of essential tremor. double-blind comparative study with one-year follow-up. Parkinsonism Relat Disord 10(1):29–33
pubmed: 14499204
doi: 10.1016/S1353-8020(03)00070-1
Sethi KD, Zamrini EY (1990) Asymmetry in clinical features of drug-induced parkinsonism. J Neuropsychiatry Clin Neurosci 2(1):64–66
pubmed: 1983774
doi: 10.1176/jnp.2.1.64
Shah C, Jackson GR, Sarwar AI, Mandava P, Jamal F (2022) Treatment patterns in essential tremor: a retrospective analysis. Tremor Other Hyperkinet Mov (n Y) 12:10
pubmed: 35415009
doi: 10.5334/tohm.682
Shahien M, Elaraby A, Gamal M et al (2023) Physical therapy interventions for the management of hand tremors in patients with Parkinson’s disease: a systematic review. Neurol Sci 44(2):461–470
pubmed: 36205810
doi: 10.1007/s10072-022-06420-1
Shahsavar Y, Ghoshuni M, Talaei A (2018) Quantifying clinical improvements in patients with depression under the treatment of transcranial direct current stimulation using event related potentials. Australas Phys Eng Sci Med 41(4):973–983
pubmed: 30390213
doi: 10.1007/s13246-018-0696-x
Sharma S, Pandey S (2019) Treatment of essential tremor: current status. Postgrad Med J 96(1132):84–93
pubmed: 31575730
doi: 10.1136/postgradmedj-2019-136647
Sheng Y, Zhou X, Yang S, Ma P, Chen C (2021) Modelling item scores of unified Parkinson’s disease rating scale part III for greater trial efficiency. Br J Clin Pharmacol 87(9):3608–3618
pubmed: 33580584
doi: 10.1111/bcp.14777
Simpson DM, Blitzer A, Brashear A et al (2008) Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70(19):1699–1706
pubmed: 18458230
doi: 10.1212/01.wnl.0000311389.26145.95
Sirota RA, Kimmel PL, Trichtinger MD, Diamond BF, Stein HD, Yudis M (1986) Metoclopramide-induced parkinsonism in hemodialysis patients. report of two cases. Arch Intern Med 146(10):2070–2071
pubmed: 3767555
doi: 10.1001/archinte.1986.00360220252041
Smith SC, Wagner MS (2014) Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett 35(3):198–201
pubmed: 24977967
Tedeschi G, Sasso E, Marshall RW, Bonavita V (1990) Tremor in Parkinson disease: acute response to oral levodopa. Ital J Neurol Sci 11(3):259–263
pubmed: 2201664
doi: 10.1007/BF02333855
Tinsley RB, Bye CR, Parish CL et al (2009) Dopamine D2 receptor knockout mice develop features of Parkinson disease. Ann Neurol 66(4):472–484
pubmed: 19847912
doi: 10.1002/ana.21716
Tonges L, Buhmann C, Klebe S et al (2022) Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice. J Neural Transm (vienna) 129(9):1201–1217
pubmed: 35428925
doi: 10.1007/s00702-022-02498-1
Tsuboi T, Jabarkheel Z, Zeilman PR et al (2020) Longitudinal follow-up with VIM thalamic deep brain stimulation for dystonic or essential tremor. Neurology 94(10):e1073–e1084
pubmed: 32047071
pmcid: 7238918
doi: 10.1212/WNL.0000000000008875
van de Wardt J, van der Stouwe AM, Dirkx M et al (2020) Systematic clinical approach for diagnosing upper limb tremor. J Neurol Neurosurgamp Psychiatry 91(8):822–830
doi: 10.1136/jnnp-2019-322676
van Holstein M, Aarts E, van der Schaaf ME et al (2011) Human cognitive flexibility depends on dopamine D2 receptor signaling. Psychopharmacology 218(3):567–578
pubmed: 21611724
pmcid: 3210362
doi: 10.1007/s00213-011-2340-2
Velasco FC, Molina-Negro P, Bertrand C, Hardy J (1972) Further definition of the subthalamic target for arrest of tremor. J Neurosurg 36(2):184–191
pubmed: 4550420
doi: 10.3171/jns.1972.36.2.0184
Vescio B, Quattrone A, Nistico R, Crasa M, Quattrone A (2021) Wearable devices for assessment of tremor. Front Neurol 12:680011
pubmed: 34177785
pmcid: 8226078
doi: 10.3389/fneur.2021.680011
Voller B, Lines E, McCrossin G et al (2016) Dose-escalation study of octanoic acid in patients with essential tremor. J Clin Invest 126(4):1451–1457
pubmed: 26927672
pmcid: 4811161
doi: 10.1172/JCI83621
Wang J, Liu ZL, Chen B (2001) Dopamine D5 receptor gene polymorphism and the risk of levodopa-induced motor fluctuations in patients with Parkinson’s disease. Neurosci Lett 308(1):21–24
pubmed: 11445276
doi: 10.1016/S0304-3940(01)01971-1
Wang S, Wacker D, Levit A et al (2017) D(4) dopamine receptor high-resolution structures enable the discovery of selective agonists. Science 358(6361):381–386
pubmed: 29051383
pmcid: 5856174
doi: 10.1126/science.aan5468
Wang S, Che T, Levit A, Shoichet BK, Wacker D, Roth BL (2018) Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone. Nature 555(7695):269–273
pubmed: 29466326
pmcid: 5843546
doi: 10.1038/nature25758
Warmerdam E, Hausdorff JM, Atrsaei A et al (2020) Long-term unsupervised mobility assessment in movement disorders. Lancet Neurol 19(5):462–470
pubmed: 32059811
doi: 10.1016/S1474-4422(19)30397-7
Weaver FM, Follett K, Stern M et al (2009) Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 301(1):63–73
pubmed: 19126811
pmcid: 2814800
doi: 10.1001/jama.2008.929
Wharen RE Jr, Okun MS, Guthrie BL et al (2017) Thalamic DBS with a constant-current device in essential tremor: a controlled clinical trial. Parkinsonism Relat Disord 40:18–26
pubmed: 28400200
doi: 10.1016/j.parkreldis.2017.03.017
Wijdicks EF, Wiesner RH, Dahlke LJ, Krom RA (1994) FK506-induced neurotoxicity in liver transplantation. Ann Neurol 35(4):498–501
pubmed: 7512320
doi: 10.1002/ana.410350422
Williams A, Gill S, Varma T et al (2010) Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 9(6):581–591
pubmed: 20434403
pmcid: 2874872
doi: 10.1016/S1474-4422(10)70093-4
Wilson SM, Wurst MG, Whatley MF, Daniels RN (2020) Classics in chemical neuroscience: pramipexole. ACS Chem Neurosci 11(17):2506–2512
pubmed: 32786316
doi: 10.1021/acschemneuro.0c00332
Wong JK, Cauraugh JH, Ho KWD et al (2019) STN vs. GPi deep brain stimulation for tremor suppression in Parkinson disease: A systematic review and meta-analysis. Parkinsonism Relat Disord 58:56–62
pubmed: 30177491
doi: 10.1016/j.parkreldis.2018.08.017
Yaw TK, Fox SH, Lang AE (2016) Clozapine in Parkinsonian rest tremor: a review of outcomes, adverse reactions, and possible mechanisms of action. Mov Disord Clin Pract 3(2):116–124
pubmed: 30363578
doi: 10.1002/mdc3.12266
Zaaroor M, Sinai A, Goldsher D, Eran A, Nassar M, Schlesinger I (2018) Magnetic resonance-guided focused ultrasound thalamotomy for tremor: a report of 30 Parkinson’s disease and essential tremor cases. J Neurosurg 128(1):202–210
pubmed: 28298022
doi: 10.3171/2016.10.JNS16758
Zach H, Dirkx MF, Pasman JW, Bloem BR, Helmich RC (2017) Cognitive stress reduces the effect of levodopa on Parkinson’s resting tremor. CNS Neurosci Ther 23(3):209–215
pubmed: 28071873
pmcid: 5324662
doi: 10.1111/cns.12670
Zadikoff C, Munhoz RP, Asante AN et al (2007) Movement disorders in patients taking anticonvulsants. J Neurol Neurosurg Psychiatry 78(2):147–151
pubmed: 17012337
doi: 10.1136/jnnp.2006.100222
Zesiewicz TA, Elble RJ, Louis ED et al (2011) Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology. Neurology 77(19):1752–1755
pubmed: 22013182
pmcid: 3208950
doi: 10.1212/WNL.0b013e318236f0fd
Zesiewicz TA, Shaw JD, Allison KG, Staffetti JS, Okun MS, Sullivan KL (2013) Update on treatment of essential tremor. Curr Treat Options Neurol 15(4):410–423
pubmed: 23881742
doi: 10.1007/s11940-013-0239-4
Zhang CQ, He BM, Hu ML, Sun HB (2020) Risk of valproic acid-related tremor: a systematic review and meta-analysis. Front Neurol 11:576579
pubmed: 33384651
pmcid: 7769765
doi: 10.3389/fneur.2020.576579
Zou H, Aggarwal V, Stebbins GT et al (2022) Application of longitudinal item response theory models to modeling Parkinson’s disease progression. CPT Pharm Syst Pharmacol 11(10):1382–1392
doi: 10.1002/psp4.12853